Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Bullboard Posts
Comment by canadapieton Jun 17, 2019 1:30pm
101 Views
Post# 29832884

RE:RE:RE:Silver lining

RE:RE:RE:Silver liningSPCEO1 - (6/17/2019 1:22:06 PM) 
RE:RE:Silver lining
I just thought it is worth reiterating that TH this morning told us, if ever so imperfectly, that they have a new business franchise in HIV NASH that very likely is worth hundreds of millions of dollars. Somehow, that seems to have been missed by Mr. Market, that ever-irrational beast. Now, I know TH's presentation style makes investors work a little to suss that out, but it really is pretty easy to calculate. As you noted below Wino115, the market size numbers they presented today were mostly much higher than what I ahd been assuming. We need to work out the F0 versus F1-F3 thing, however, as I am sensing it may be only the F1-F3 patients that matter to the FDA. IF they are the only ones that the FDA actually care about, then we may be looking at 100,0000 possible patients with HIV NASH that the FDA is will to approve a drug to treat them. EVen so, I still suspect they could get 4-6,000 of those on treatment and that translates into a lot of revenues and earnings when you own the HIV NASH market and can charge a price of $60,000 or so by the time Egrifta is commercialized for HIV NASH.  

No matter how bad some think TH did in presenting their case today, the reaction to what is clearly a new franchise for them, which is likely now their biggest franchise of all, is off the charts ridiculous. The stock should be up 50%.  


Like i said before , you are the optimist and the Promotor of our company !!! 
50% higher, a bit like CTRV........But i agree the market is missing the real value (i think) so i added to my position!! 
And you know mister SPCEO, whenever "the dubble" comes, you can/may visit "the city of Ghent" in my country!!! 


Thx for clarifying and glty 
Bullboard Posts